JOHN DAVID KIRSCH
Pharmacy in Waynesburg, PA
License number
Pennsylvania RP037486L
Category
Pharmacy
Type
Pharmacist
Address
Address
Waynesburg, PA 15370
Personal information
See more information about JOHN DAVID KIRSCH at radaris.comName
Address
Phone
495 Markle St, Philadelphia, PA 19128
6 Antietam Dr, Birdsboro, PA 19508
990 Natalie Ln, Coopersburg, PA 18036
998 Redwood Dr, Pittsburgh, PA 15234
988 Worthington Dr, Warminster, PA 18974
Professional information
Compositions And Methods For Inhibiting Bone Resorption
US Patent:
2005026, Nov 24, 2005
Filed:
May 19, 2004
Appl. No.:
10/848503
Inventors:
Anastasia Daifotis - Westfield NJ, US
Andrew Denker - Hoboken NJ, US
Craig Ikeda - Harleysville PA, US
Bogdan Matuszewski - North Wales PA, US
Sid Mazel - Basking Ridge NJ, US
Arturo Porras - Lansdale PA, US
Art Santora - Watchung NJ, US
Randal Seburg - Collegeville PA, US
Limin Zhu - Collegeville PA, US
John Yates - Libertyville IL, US
John Kirsch - Waynesburg PA, US
Andrew Denker - Hoboken NJ, US
Craig Ikeda - Harleysville PA, US
Bogdan Matuszewski - North Wales PA, US
Sid Mazel - Basking Ridge NJ, US
Arturo Porras - Lansdale PA, US
Art Santora - Watchung NJ, US
Randal Seburg - Collegeville PA, US
Limin Zhu - Collegeville PA, US
John Yates - Libertyville IL, US
John Kirsch - Waynesburg PA, US
International Classification:
A61K031/675, A61K031/59, A61K031/663
US Classification:
514089000, 514102000, 514167000
Abstract:
Disclosed are compositions and methods for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin Dsuitable for once-weekly dosing. Compositions and methods of the invention provide vitamin D nutrition during bisphosphonate treatment to facilitate normal bone formation and mineralization while minimizing the occurrence of or potential for the complications associated with vitamin D insufficiency, such as hypocalcaemia and osteomalacia. Also disclosed are methods for manufacturing compositions of the present invention, for measuring stability and degradation of those compositions, and for measuring blood plasma levels of vitamin D.
Sustained Release Delivery Of A Thrombin Inhibitor
US Patent:
2004021, Oct 28, 2004
Filed:
Apr 22, 2004
Appl. No.:
10/829737
Inventors:
Eleni Dokou - Lansdale PA, US
Sally Harding - Impington, GB
Shyam Karki - Lansdale PA, US
John Kirsch - Waynesburg PA, US
Maneesh Nerurkar - Lansdale PA, US
Kendal Pitt - Welwyn Graden City, GB
Sally Harding - Impington, GB
Shyam Karki - Lansdale PA, US
John Kirsch - Waynesburg PA, US
Maneesh Nerurkar - Lansdale PA, US
Kendal Pitt - Welwyn Graden City, GB
International Classification:
A61K009/24
US Classification:
424/472000
Abstract:
The invention is an oral pharmaceutical composition comprising a) a tablet core comprising a therapeutically effective amount of 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, or a pharmaceutically acceptable salt thereof, a water swellable polymer, and a neutralizing agent, and b) a water insoluble film coating surrounding the tablet core, wherein the water insoluble film coated tablet core has a plurality of apertures.